Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 176 In stock
USD 110 In stock
USD 170 In stock
USD 270 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
ATR [12]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM 1.8 μM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVztPVZUOi53IN88US=> NWnRcppSOS12IHS= MUnEUXNQ Moey[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> NUO5UmNmOjV2OUCzPFM>
H1703 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnLW25NOi53IN88US=> NW\FWVFbOS12IHS= NYjHVo9tTE2VTx?= MkDR[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> M3zxUlI2PDlyM{iz
HUVECs M1TlNmN6fG:2b4jpZ4l1gSCDc4PhfS=> M{TPSVExOCCwTR?= M3TlVFI1KGh? NFS3XlFifHSnboXheIV{KHSqZTDhZpJw\2G2aY\lJIVn\mWldIOgc4Yh[2GueXPvd4lvKG:wIG\STU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NHPqN|MzPTR3MEG4Oi=>
APRE-19 MXXBdI9xfG:|aYOgRZN{[Xl? NXixUZFGPSEQvF2= MoLpNlQhcA>? NEPVdW5i[m:uaYPo[ZMhTkycLX3l[IlifGWmIIDyc{1{fXK4aY\hcE9idnSrLXHwc5B1d3OrczDhZ5Rqfmm2eR?= MkPUNlU{Ojl4MUe=
MDA-MB-231 M3;JTWFxd3C2b4Ppd{BCe3OjeR?= M3PkT|HDqM7:TdMg MUG0PEBp M{LCVWROW09? MnL2[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJJRz\WG2ZXSge4l1cCB{NTFOwG0hd2ZiRkGgc5IhTjJiwrC= NHXrSXkzPTNyMEmzNi=>
MCF7 Ml3SSpVv[3Srb36gRZN{[Xl? Mnf5NVAxKG6P MnPjNlQhcA>? NWK3dHhu\WyrbXnuZZRmeyCHMj3pcoR2[2WmIFHSSU1NfWNiYXP0bZZqfHl? NVL1VHV4OjVzN{K1OVc>
HT-29  M1Xpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjVRZkyNjYEoNM1US=> M2\xbFk3KGh? M2XjXIRm[3KnYYPld{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWgbY5pcWKrdHXkJIJ6KEu\TlG= M4CwPFI2ODF{MUKz
MO59K  MYrDfZRwfG:6aXPpeJkhSXO|YYm= NYXaXmF2PcLizszN M1vRb|ch\A>? NIe5R4xFVVOR MV7lcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NV7EZWUxOjR7NUO1OlE>
MO59J NH:3XYtEgXSxdH;4bYNqfHliQYPzZZk> NHr6R442yqEQvF2= M2XDV|ch\A>? MkS3SG1UVw>? NWT1cYhY\W6qYX7j[ZMhfGinIHP5eI91d3irY3n0fUBw\iCndH;wc5Nq\GVib4KgZ4l{eGyjdHnu MUCyOFk2OzV4MR?=
MO59K  M{DPcWFxd3C2b4Ppd{BCe3OjeR?= M3nITFExKM7:TR?= NVr2PWU6OjRiaB?= M1;2TGROW09? NHfvb2ZqdmO{ZXHz[ZMhfGinIFTTRkBt\X[nbDDpcoR2[2WmIHL5JIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? MmjBNlQ6PTN3NkG=
MO59J NF3TdFlCeG:ydH;zbZMhSXO|YYm= NEW3eGMyOCEQvF2= M4rQc|I1KGh? NVHZdZRmTE2VTx?= MWjpcoNz\WG|ZYOgeIhmKESVQjDs[ZZmdCCrbnT1Z4VlKGK7IHX0c5Bwe2mmZTDvdkBkcXOybHH0bY4> Mk[2NlQ6PTN3NkG=
HepG2 MlOzSpVv[3Srb36gRZN{[Xl? M{S1WFExOCCwTR?= M4H1bFAvPSCq NYPhNFZwTE2VTx?= MVHicI9kc3NiTVGtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;u NVjodFhOOjR6NkOzOVA>
A549  M3j0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\sSIo{KML3TdMg M3Hz[VIhcA>? NHXTWVZ{fXCycnXzd4V{KHCnbXX0doV5\WRvaX7keYNm\CCDa4SgZY5lKEeVS{ROtkBi[3SrdnH0bY9vNCCVLYDoZZNmKGG{cnXzeEwh[2WubDDhdI9xfG:|aYOgZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:w NE\pOHUzPDh2N{i2Ny=>
A549  NYjwVWJvTnWwY4Tpc44hSXO|YYm= NF7mV2gyOMLizsztxsA> MWCxOkBp MW\EUXNQ MlvHcY9lfWyjdHXzJJRp\SCLQW[gdoVxdGmlYYTpc44h[W6mIHPheZNmeyC{ZYTlcpRqd25ib3[gUnAhcW5idHjlJI52[2yndYOu M4\GSFI1QDB{MUGx
SK-N-LO MX\GeY5kfGmxbjDBd5NigQ>? MlWxNVAxKG6P NVjqUYZROC53IHi= NIXTe5Bl\WO{ZXHz[ZMhfGinIIP0bY12dGGwdDDl[oZm[3S|IH;mJI1wenCqaX7lJI9vKEGtdDDwbI9{eGixconsZZRqd25? NXKwVZNUOjR4NUS2NFY>
HL-60 NIfsfIZHfW6ldHnvckBCe3OjeR?= MUGwMlHDqM7:TR?= MYi3NkBp MornZoxw[2u|IHThd4F1cW6rYj3pcoR2[2WmIHPlcIwh\GmoZnXy[Y51cWG2aX;u MmrvNlQ3ODd{N{O=
HepG2  M{ThcmZ2dmO2aX;uJGF{e2G7 NHOySXkzODBibl2= M1rl[|AvPSCq MW\heJRmdnWjdHXzJGZwgE9icHjvd5Bpd3K7bHH0bY9v M4XjOFI1PTN3MUmy
H520 M{WxcmZ2dmO2aX;uJGF{e2G7 M4PYTFExyqEQvF2= NWDoNVM5OSCq NVvTSJJSTE2VTx?= MkPp[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz NVv4eWdPOjR2NEe5N|U>
H1975 MkLRSpVv[3Srb36gRZN{[Xl? M4X1WVExyqEQvF2= NHrudmoyKGh? MUnEUXNQ M2jrb4Rm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> M1;sNFI1PDR5OUO1
MG-63 NILDZ4xCeG:ydH;zbZMhSXO|YYm= MVWxNEDDvU1? NV\ZXItUOTJiaB?= NGjIWGxmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? Ml;vNlQ{PTh|MEG=
5637 Mki4RZBweHSxc3nzJGF{e2G7 M2K2dFExyqEQvF2= NELydII1OCCvaX6= NXizRnI3emW4ZYLz[ZMheDJzV1HGNUBmgHC{ZYPzbY9vNCCFRFug[ZhxemW|c3nvckwh[W6mIHPlcIwhcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IH\1Z49q\GGw MVuyOFM{Ozh4OB?=
HEK-293 NUP2bHZkTnWwY4Tpc44hSXO|YYm= NIfV[HEyPTCwTR?= M1WyfFE3KGh? NXHrNng{TE2VTx?= NHGzNHhl\WO{ZXHz[ZMhS1KWIHHjeIl3cXS7 M1frRlI1OzJ2M{[2
SW480  MWnGeY5kfGmxbjDBd5NigQ>? NWXlflhTOTVybl2= NEDjZ|kzOCCq NYPSbm11TE2VTx?= NVPhbHhGemWmdXPld{Bk\WyudXzhdkBi[2O3bYXsZZRqd25ib3[g{tIu[2G2ZX7pci=> MUiyOFMzPDN4Nh?=
HepG2 Mo\rSpVv[3Srb36gRZN{[Xl? MX[xNFAhdk1? M2roWlI1KGh? NV:xb2hD[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= MkHBNlQzQTd3MUC=
HCT 116  NX22RVBTTnWwY4Tpc44hSXO|YYm= M1[zXVExOCCwTR?= MmnENlQhcA>? M37RUoF1fGWwdXH0[ZMhfGinIHPvcI9vcWW|IH;mJJRp\SC2dX3vdkBk\WyuczD3bZRpKHWycnXneYxifGmxbjDv[kBCc3Rz NW\OfnE2OjR{OUe1NVA>
BEL/FU MnTXSpVv[3Srb36gRZN{[Xl? Mnu0NUBuVQ>? MoPjNlQhcA>? M3PVdYRm[3KnYYPld{Bxem:2ZXnuJIxmfmWuczDv[kB1cGViUFmzT{9Cc3RicHH0bJdigQ>? NVzjOGhWOjR{M{KwPVk>
Huh7  NUTrbGFoTnWwY4Tpc44hSXO|YYm= NXfmVFV5O8LizszN M{DlfVEhcA>? NVzvWYU2emWmdXPld{B1cGVidnnyeZMh\W62comgbY51dyC2aHWgZ4VtdHN? MkTvNlQyQDRzOU[=
A-375 NWn6RpdrSXCxcITvd4l{KEG|c3H5 M37vblQwQCEQvF2= M13sXFI1KGh? NVK5[JAy\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M1XYNlI1OTF|MUez
A-375-TS  NUXhUY1RSXCxcITvd4l{KEG|c3H5 Ml3TOE85KM7:TR?= MVGyOEBp NXjtNJcx\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MnXTNlQyOTNzN{O=
Mel-HO NXToSJdwSXCxcITvd4l{KEG|c3H5 NGD2dGI1NzhizszN NWrJSZFoOjRiaB?= M4XyRYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NVXrd|dkOjRzMUOxO|M>
Mel-HO-TS MWjBdI9xfG:|aYOgRZN{[Xl? NUnSZ2FUPC96IN88US=> MUiyOEBp MV;lcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MXmyOFEyOzF5Mx?=
MeWo NVT6U2tZSXCxcITvd4l{KEG|c3H5 Mnz6OE85KM7:TR?= Mmr5NlQhcA>? M33VVoVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NGT0ZoczPDFzM{G3Ny=>
Mel-2a NFrNdlVCeG:ydH;zbZMhSXO|YYm= M3XV[VQwQCEQvF2= MnfSNlQhcA>? NXjMU5Jz\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M4\TdFI1OTF|MUez
MDA-MB-231 NGq0fHdHfW6ldHnvckBCe3OjeR?= MlXENQKBmzRyMDDuUS=> M2[ydlQhcA>? NUnEfnhLe3WycILld5NmeyCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVOyNlkxPjJ3OR?=
MDA-MB-231 MlL2SpVv[3Srb36gRZN{[Xl? MVW0NFAhdk1? M2PUPFQhcA>? MkSw[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4TMdVIzQTB4MkW5
Jurkat MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CwO|AvOjVvMT6yOUDPxE1? NH;uVVEzPC92ODDo NF3oZ5lFVVOR MX;pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? MojxNVk4PTdzOEW=
Namalwa MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3BbGZWOC5{NT2xMlI2KM7:TR?= MkT3NlQwPDhiaB?= NWnjbHl2TE2VTx?= NXPPeVdlcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NWC4Wnp{OTl5NUexPFU>
Jurkat MkfXRZBweHSxc3nzJGF{e2G7 NGm5OnAxNjJ3LUGuNlUh|ryP NUewPYtXOjRxNEigbC=> MWPEUXNQ M2rRT4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NFPCbY4yQTd3N{G4OS=>
Namalwa NIe5cZFCeG:ydH;zbZMhSXO|YYm= NGe3VVYxNjJ3LUGuNlUh|ryP NF;BO3MzPC92ODDo M1[zVmROW09? NWjiPFdYcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz M1TFb|E6PzV5MUi1
K562 Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLwNlQhcA>? MYPJR|UxRTJ3wsGwMlE1KG6P MmLQNVk3PjJ|NkG=
SW1990 MVzGeY5kfGmxbjDBd5NigQ>? NUXGWXdVOC5yMT2xJO69VQ>? NX3nW3FCOSCq NFOxc5lqdmirYnn0d{BJSS2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25? Mn[2NVk1PjlyMkC=
RT112  MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlToNVDDqM7:TR?= NEHMSW0zPCCq MontSG1UVw>? M4LodIRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ M4j3c|E5Pzh5OEOy
MHG-U1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXSTFUyOMLizszN M3jaRVI1KGh? M4Pv[2ROW09? NHrMWXZl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? NEKxdoMyQDd6N{izNi=>
SMMC-7721 M2ftV2Fxd3C2b4Ppd{BCe3OjeR?= MoHFNlAxyqCwTR?= NH\3cnAzPCCq NFjiWJFqdmO{ZXHz[ZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| M4\LcVE4PTV5MUmx
SMMC-7721 MkLCSpVv[3Srb36gRZN{[Xl? NX73OFVQOjBywrDuUS=> NEj3OoczPCCq M3LG[ZVxNXKnZ4XsZZRmeyEQskGsOGdVOSCneIDy[ZN{cW:w NHK0bnUyPzV3N{G5NS=>
HeLa Mo\6SpVv[3Srb36gRZN{[Xl? Mn7TNVAxyqCwTdMg M4LvPVEhcA>? NUXQXJpr[Wy2ZYLzJJRp\SCvb4LwbI9td2e7IH;mJJRp\SC2cnHud4ZmenKrbjDy[YN6[2yrbnegZ49ueGG{dH3lcpQ> NVfWNYs3OTZ6OUC5NVU>
MRC5VI M2PWd2Z2dmO2aX;uJGF{e2G7 MV:xNk42KG2P Ml[xNE42KGh? MV;EUXNQ M{jENIFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NH[1N3IyPjJ{N{O5OC=>
AT5BIVA MmrhSpVv[3Srb36gRZN{[Xl? MWSxNk42KG2P M1vhVlAvPSCq NX;uUHZ1TE2VTx?= NGHmeFFi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? M3\KfVE3OjJ5M{m0
M059J MlnvSpVv[3Srb36gRZN{[Xl? MnzQNVIvPSCvTR?= NVjUfIIxOC53IHi= MWDEUXNQ Mln5ZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> NXjnN|ZuOTZ{MkezPVQ>
HeLa MWTGeY5kfGmxbjDBd5NigQ>? NUD1UoZuOTJwNTDtUS=> NEHtcXExNjViaB?= NYD3RoZJTE2VTx?= NU\oVYlJ[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? NXG2SZBTOTZ{MkezPVQ>
N2a MmTiRZBweHSxc3nzJGF{e2G7 NHHQbmcxNjFvMUCg{txO NX;FWYRbOiCq MXzpcoR2[2W|IHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NGfhb5EyPTh2Mke2Oy=>
Jurkat  MXvLbY5ie2ViQYPzZZk> M4O0[2lEPTBib3[gNlQhdk1? NGrrUYEyPTZ4NEWxPS=>

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5%DMSO+corn oil 11mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID